Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €9.20 EUR
Change Today +0.028 / 0.31%
Volume 0.0
MXE On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 1:36 PM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

mimedx group inc (MXE) Snapshot

Open
€9.20
Previous Close
€9.17
Day High
€9.20
Day Low
€9.20
52 Week High
04/13/15 - €10.34
52 Week Low
06/4/14 - €3.90
Market Cap
999.4M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
108.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MIMEDX GROUP INC (MXE)

Related News

No related news articles were found.

mimedx group inc (MXE) Related Businessweek News

No Related Businessweek News Found

mimedx group inc (MXE) Details

MiMedx Group, Inc. designs, manufactures, and markets products and tissue processing services in the United States. The company’s products include patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies comprise AmnioFix and EpiFix, which are tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through the company’s donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. It processes the human amniotic membrane utilizing its proprietary PURION process to produce allograft, an easy to use and effective implant. The company also provides CollaFix, a medical device technology platform, that creates fibers from soluble collagen and a specialized cross-linking process; and HydroFix products, which are based on licenses to patents and patent application rights to a PVA- based hydrogel, a water-based biomaterial. It supplies amniotic tissue approximately 350,000 allografts on OEM basis for application in the wound care, surgical, sports medicine, ophthalmic, and dental sectors of healthcare through direct sales force, independent sales representatives, and distributors, as well as through private label or OEM relationships. The company is headquartered in Marietta, Georgia.

386 Employees
Last Reported Date: 03/13/15

mimedx group inc (MXE) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $914.9K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $422.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $295.0K
Advisory Counsel
Total Annual Compensation: $256.6K
Compensation as of Fiscal Year 2014.

mimedx group inc (MXE) Key Developments

MiMedx Group, Inc. Announces Amendment to the Articles of Incorporation

The Annual Meeting of Shareholders of MiMedx Group, Inc. held on May 14, 2015, has approved Amendment to the Articles of Incorporation to increase the number of authorized shares of common stock from 130,000,000 to 150,000,000.

MiMedx Group, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Second Quarter and Full Year of 2015

MiMedx Group, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net sales of $40,767,000 against $19,559,000 a year ago. Operating income was $4,247,000 against operating loss of $891,000 a year ago. Income before income tax provision was $4,233,000 against loss before income tax provision of $912,000 a year ago. Net income was $4,087,000 or $0.04 per basic and diluted share against net loss of $922,000 or $0.01 per basic and diluted share a year ago. Net cash flows from operating activities were $4,210,000 against net cash flows used in operating activities of $1,612,000 a year ago. Purchases of equipment were $1,347,000 against $466,000 a year ago. Patent application costs were $201,000 against $168,000 a year ago. Adjusted EBITDA were $8,767,000 against $1,975,000 a year ago. Positive cash flow from operating activities for the quarter was driven mainly by an increase in adjusted EBITDA, somewhat offset by increased working capital. The improvement in adjusted EBITDA driven by increased sales volume, improved gross margins and the corresponding operating leverage. For the second quarter of 2015, the company’s revenue expected to be in the range of $44.0 million to $46 million and operating profit in excess of 11%. For the full year of 2015, the company’s revenue expected to be in the range of $180 million to $190 million and operating profit margin for full year 2015 in excess of 15%. The company assume that 3% to 5% tax rate for the balance of the year.

MiMedx Group, Inc. Reports Revenue Results for the First Quarter Ended March 31, 2015; Reiterates Revenue Guidance for Full Year of 2015

MiMedx Group, Inc. reported revenue results for the first quarter ended March 31, 2015. The company recorded revenue for the quarter ended March 31, 2015 of $40.8 million, a $21.2 million or 108% increase over first quarter of 2014 revenue of $19.6 million. The company reiterated its previously communicated guidance for full year 2015 revenue to be in the range of $175.0 million to $190.0 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MXE:GR €9.20 EUR +0.028

MXE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliqua BioMedical Inc $4.58 USD +0.18
Derma Sciences Inc $6.71 USD +0.15
Medtronic PLC $77.82 USD -0.59
Osiris Therapeutics Inc $18.20 USD -0.16
Smith & Nephew PLC 1,134 GBp -6.00
View Industry Companies
 

Industry Analysis

MXE

Industry Average

Valuation MXE Industry Range
Price/Earnings 100.0x
Price/Sales 7.7x
Price/Book 12.8x
Price/Cash Flow 91.2x
TEV/Sales 7.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MIMEDX GROUP INC, please visit www.mimedx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.